Investment Logic:
It is a leader in Biosimilars. In the past Biocon Biologics had acquired the biosimilars business from Viatris. Now, it has successfully concluded the transition of the acquired biosimilars business from Viatris in 120 countries. Thus market share gain in biosimilars will bring healthy operating cash flow.
signed a partnership agreement with Juno Pharmaceuticals in Canada, for the commercialization of Liraglutide, used in the treatment of Type-2 diabetes and obesity.
Biocon invested 1 billion USD in the acquisition of Viatris, which led to heavy debt on the books. Management is planning to divest its non-core assets to bring down its net debt by 50%.
In the immunology segment, it has 15 products under development in the pipeline, targeting USD100 billion over the next 10 years.
It is a leader in Biosimilars. In the past Biocon Biologics had acquired the biosimilars business from Viatris. Now, it has successfully concluded the transition of the acquired biosimilars business from Viatris in 120 countries. Thus market share gain in biosimilars will bring healthy operating cash flow.
signed a partnership agreement with Juno Pharmaceuticals in Canada, for the commercialization of Liraglutide, used in the treatment of Type-2 diabetes and obesity.
Biocon invested 1 billion USD in the acquisition of Viatris, which led to heavy debt on the books. Management is planning to divest its non-core assets to bring down its net debt by 50%.
In the immunology segment, it has 15 products under development in the pipeline, targeting USD100 billion over the next 10 years.
交易進行
took support after correction and the stock is ready for some quick moves註釋
GST Council has slashed the GST rate on cancer drugs from 12% to 5% on 9th Sep 2024. BIOCON, which manufactures anti-cancer drugs like Dasatinib, Lenalidomide, Pazopanib, Erdafitinib is likely to be impacted positively. 
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。